Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02840409 · ClinicalTrials.gov registry record · Phase 2
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
A Phase 2 study of Low Grade Glioma, sponsored by The Hospital for Sick Children.
- Active
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
- 20
- Study locations
NCT02840409: Active Phase 2 study of Low Grade Glioma, sponsored by The Hospital for Sick Children.
NCT02840409 is a Phase 2 study of Low Grade Glioma that is active but no longer recruiting, run by The Hospital for Sick Children. The registered enrollment target is 109 participants, roughly in line with the 109-participant average among 23 other Low Grade Glioma trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02840409, a Phase 2 study of Low Grade Glioma, is active but no longer recruiting, sponsored by The Hospital for Sick Children.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy naïve pediatric patients with progressive Low Grade Glioma aged 6 months to less than18 years of age at the time of initiation of therapy. Participants will be randomized to Arm A or Arm B. Arm A includes 68 weeks of single agent Vinblastine administered once weekly IV. Arm B includes 68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks. Randomization will take place at the time of registration taking into account NF1 and BRAF-KIAA1549-fusion status.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Vinblastine
Study Locations (20)
Ontario
- McMaster Children's Hospital - Hamilton
- Children's Hospital - London Health Sciences Centre - London
- The Hospital for Sick Children - Toronto
Quebec
- Centre Hospitalier Universitaire Sainte-Justine - Montreal
- Montreal Children's Hospital - Montreal
- CHU du Quebec-Universite Laval - Québec
Alberta
- Alberta Children's Hospital - Calgary
- Stollery Children's Hospital - Edmonton
California
- Children's Hospital Los Angeles - Los Angeles
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Atlanta
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What the registry record for NCT02840409 still lists
NCT02840409 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 109-participant average among 23 other Low Grade Glioma trials with a reported enrollment target.
The record links to 1 condition, with Low Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02840409 names 20 study sites across 15 states, led by Ontario, Quebec, Alberta.
Frequently Asked Questions
What is clinical trial NCT02840409 about?
NCT02840409 is a clinical study titled "Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)". This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy naïve pediatric patients with progressive Low Grade Glioma aged 6 months to less than18 years of age at the time of initiation of therapy. Participants wil...
What is the current status of trial NCT02840409?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2016-08-01. Estimated completion is 2026-08.
What conditions does trial NCT02840409 study?
This clinical trial studies the following conditions: Low Grade Glioma.
What interventions are being tested in trial NCT02840409?
The interventions under investigation include: Bevacizumab (DRUG), Vinblastine (DRUG).
Who is sponsoring clinical trial NCT02840409?
This trial is sponsored by The Hospital for Sick Children, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02840409 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Georgia, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02840409's enrollment target sits among peer trials
109 10th of 23 higher than 14 of 23 other Low Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Low Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Vaccine Trial for Low Grade Gliomas
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
RECRUITING · Phase 2
-
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI